Skip to Main Content

Paper Details

A double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting glucagon analogue, in healthy subjects.
Diabetes, Obesity and Metabolism
3
2022
HM15136, amino acids, glucagon, glucose, incretin hormones, insulin, nausea
Author NameAffiliation
Young Min ChoSeoul National University College of Medicine
  • 1 - 1

Datasets

Release 1.2